(Q38168915)

30 August 2017

title

Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations (English)

1 reference

30 August 2017

1 reference

Kerry-Ann F O'Grady

1

0 references

Anne B Chang

object named as

Anne B Chang

series ordinal

2

0 references

Keith Grimwood

series ordinal

3

object named as

Keith Grimwood

1 reference

30 August 2017

publication date

2 December 2013

1 reference

Expert Review of Respiratory Medicine

30 August 2017

published in

1 reference

30 August 2017

volume

8

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

43-55

1 reference

Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a random

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Detection of multiple respiratory pathogens during primary respiratory infection: nasal swab versus nasopharyngeal aspirate using real-time polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

New aspects on human rhinovirus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Breathing new life into pneumonia diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Viruses associated with pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Respiratory complications in children hospitalized with varicella.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

The burden of invasive pneumococcal disease and the potential for reduction by immunisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Infection in the pathogenesis and course of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Asthma as a risk factor for invasive pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Increased risk of serious pneumococcal disease in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Effectiveness of pneumococcal polysaccharide vaccine in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Prophylactic vaccinations in chronic obstructive pulmonary disease: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Use of pneumococcal polysaccharide vaccine in children: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

The worldwide impact of the seven-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Epidemiological, clinical, and laboratory aspects of pertussis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Strategies to control pertussis in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Waning immunity to pertussis following 5 doses of DTaP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Morbidity of pertussis in adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Increased risk of pertussis in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Bordetella species in children with cystic fibrosis: what do we know? The role in acute exacerbations and chronic course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Epidemiology of influenza A (H1N1)pdm09-associated deaths in the United States, September-October 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Influenza infection and vaccination in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Seasonal influenza: the burden of disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Principles underlying rational design of live attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Emerging data on the safety and efficacy of influenza vaccines in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Influenza vaccination in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Influenza: marketing vaccine by marketing disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Insights into the interaction between influenza virus and pneumococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

A role for Streptococcus pneumoniae in virus-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Respiratory viral infection predisposing for bacterial disease: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Respiratory viruses predisposing to bacterial infections: role of neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Viral load and acute otitis media development after human metapneumovirus upper respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Bacterial and viral interactions within the nasopharynx contribute to the risk of acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Combined effects of antenatal receipt of influenza vaccine by mothers and pneumococcal conjugate vaccine receipt by infants: results from a randomized, blinded, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Antimicrobial resistance in Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

The burden of nonencapsulated Haemophilus influenzae in children and potential for prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

The other siblings: respiratory infections caused by Moraxella catarrhalis and Haemophilus influenzae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

A review of 151 cases of pediatric noncystic fibrosis bronchiectasis in a tertiary care center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Airway microbiology and host defences in paediatric non-CF bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Lung function decline from adolescence to young adulthood in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Reduction in the Incidence of Acute Bronchitis by an OralHaemophilus influenzaeVaccine in Patients with Chronic Bronchitis in the Highlands of Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B,

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Bacterial biofilms in the upper airway - evidence for role in pathology and implications for treatment of otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Moraxella catarrhalis, a human respiratory tract pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Current progress with Moraxella catarrhalis antigens as vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Clinical management of Staphylococcus aureus bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Microbiologic follow-up study in adult bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Challenges for a universal Staphylococcus aureus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Will there ever be a universal Staphylococcus aureus vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Is there a future for a Staphylococcus aureus vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

The role of nasal carriage in Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Pseudomonas infection in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Clinical significance of microbial infection and adaptation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Vaccine development for patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

The burgeoning burden of respiratory syncytial virus among children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Respiratory syncytial virus and asthma: speed-dating or long-term relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Proposals for the classification of human rhinovirus species A, B and C into genotypically assigned types

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Community study of role of viral infections in exacerbations of asthma in 9-11 year old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Respiratory viruses and exacerbations of asthma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Childhood asthma and infection: virus-induced exacerbations as determinants and modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Structure of a human common cold virus and functional relationship to other picornaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Influenza vaccination coverage among high-risk groups in 11 European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Barriers to adherence to COPD guidelines among primary care providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Influenza vaccination coverage and uptake predictors among Spanish adults suffering COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

The role of the bacterial microbiome in lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Seasonal influenza vaccinations: specialized products for different target groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease Protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Respiratory syncytial virus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Rhinovirus vaccination: the case against

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Respiratory Bacterial Pathogens in the Nasopharynx and Lower Airways of Australian Indigenous Children with Bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.852960

Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001958.PUB2

Identifiers

DOI

10.1586/17476348.2014.852960

1 reference

30 August 2017

1 reference